Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 11, 2017
Reporting Period: Event-based report regarding the termination of a material definitive agreement.
Key Financial Metrics
This filing does not report standard operating metrics such as revenue, profit, or cash flow for a specific period. The primary financial impact disclosed is the forgiveness of a loan balance.
- Loan Balance Forgiven: Approximately $15.6 million (including accrued interest).
- Lender: California Institute for Regenerative Medicine (CIRM).
- Pro Forma Impact: An unaudited condensed consolidated pro forma balance sheet as of September 30, 2017, is provided to reflect the removal of this liability.
Material Changes
The Company entered into Amendment No. 3 to the CIRM Notice of Loan Award (DR2A-05735) on December 11, 2017. This amendment resulted in the complete forgiveness of the Loan Balance, terminating the Company's obligation to repay the funds. This change was triggered by the abandonment of the ALLSTAR project at the end of its project period, following the completion of the final operational milestone in November 2017.
Outlook, Risks, and Management Commentary
Management Commentary: The forgiveness of the loan was a direct result of the project abandonment in accordance with the Loan Agreement and CIRM Loan Administration Policy. The Company notes that the pro forma financial information is for informational purposes only and does not necessarily reflect actual future financial positions.
Risks and Contingencies: The pro forma financial information is subject to risks and uncertainties discussed in the Company's Form 10-Q (filed November 14, 2017) and Form 10-K (filed March 16, 2017) under the "Risk Factors" section.
Investor Verification Checklist
- Verify the full text of Amendment No. 3 to the CIRM Notice of Loan Award (Exhibit 10.1) for specific terms of the forgiveness.
- Review the unaudited condensed consolidated pro forma balance sheet (Exhibit 99.1) to assess the impact on the Company's liquidity and debt position as of September 30, 2017.
- Consult the Form 10-Q for the quarter ended September 30, 2017, and the Form 10-K for the year ended December 31, 2016, for detailed financial statements and risk factors.
- Confirm the status of the ALLSTAR project and any potential future obligations related to the abandonment.